Trial Details

Not Recruiting
Basic Information
Clinical ID c3021
Identifier EUCTR2014-005192-89-FI
Trial Title _ Post-Marketing Observational Cohort Study of Patients with Inflammatory Bowel Disease (IBD) Treated with CT-P13 in Usual Clinical Practice (CONNECT-IBD)__ - CONNECT-IBD
Trial URL Visit Original Page
Study Information
Study Results

No results available
Conditions Inflamatory Bowel Disease (IBD) _ MedDRA version: 20.1_ Level: LLT_ Classification code 10021973_ Term: Inflammatory bowel disease NOS_ System Organ Class: 100000004856_ ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Interventions Trade Name: Inflectra Product Name: CT-P13 Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10- Trade Name: Remicade Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: INFLIXIMAB CAS Number: 170277-31-3 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-
Participant Information
Sponsor Hospira UK Ltd.
City -
Country/Region Portugal;Slovakia;Greece;Finland;Spain;United Kingdom;Italy;France;Czech Republic;Hungary;Belgium;Germany;Netherlands
Enrollment Criteria
Sex Requirement ALL
Age Requirement -
Study Design
Study Type Interventional clinical trial of medicinal product
Phase PHASE4
Time Information
Start Date 2025-04-24
Primary Completion Date -
Completion Date -